Log In
Print
BCIQ
Print
Print this Print this
 

PRO044

  Manage Alerts
Collapse Summary General Information
Company Prosensa Holding N.V.
DescriptionPhosphorothioate antisense oligonucleotide targeting exon 44
Molecular Target
Mechanism of Action 
Therapeutic ModalityNucleic acid: Linear RNA: Antisense
Latest Stage of DevelopmentPhase I/II
Standard IndicationMuscular dystrophy
Indication DetailsTreat Duchenne muscular dystrophy (DMD)
Regulatory Designation

U.S. - Orphan Drug (Treat Duchenne muscular dystrophy (DMD));
EU - Orphan Drug (Treat Duchenne muscular dystrophy (DMD))

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today